HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Persistent Urinary Tract Infection in Association with Community-Acquired NDM-5 Escherichia coli Clonal Group Following COVID-19 Infection - Beijing Municipality, China, 2023.

AbstractWhat is already known about this topic?:
The hospital-acquired infections caused by New Delhi metallo-beta-lactamase (NDM)-producing strains are typically attributed to a single clonal lineage.
What is added by this report?:
In this study, we encountered a unique case of community-acquired NDM-5 Escherichia coli urinary tract infection (UTI) following coronavirus disease 2019 (COVID-19). The UTI persisted for a duration of at least 45 days. Genomic analyses revealed the presence of two NDM-5 strains, both sharing an identical chromosomal background but distinct, homologous, and recombined plasmids. This case suggests that a diverse range of resistance genes may be present within the human body, with drug-resistant strains undergoing continuous evolution during infection. The intestinal tract may have been its drug-resistant gene pool.
What are the implications for public health practice?:
The observations presented in this case indicate that the endogenous acquisition of drug-resistant genes may also be an issue in managing multidrug-resistant organisms (MDRO). It is possible for continuous recombination to occur within carbapenem-resistant Enterobacteriaceae (CRE) during infection. In contrast to exogenously-acquired resistance, greater attention should be placed on the endogenous factors that contribute to the development of CRE within healthcare settings.
AuthorsJiazhen Guo, Ran Duan, Dan Zhang, Peng Zhang, Shuai Qin, Yajuan Fang, Yingna Sun, Lianhe Lu, Huaiqi Jing, Xin Wang, Rongmeng Jiang, Biao Kan
JournalChina CDC weekly (China CDC Wkly) Vol. 5 Issue 26 Pg. 565-571 (Jun 30 2023) ISSN: 2096-7071 [Electronic] China
PMID37457852 (Publication Type: Journal Article)
CopyrightCopyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: